L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
van der Putten, Louis J. M.
Visser, Nicole C.M.
van de Vijver, Koen
Kopperud, Reidun K.
Snijders, Marc P. L. M.
van den Berg-van Erp, Saskia
Salvesen, Helga B.
Massuger, Leon F. A. G.
Pijnenborg, Johanna M. A.
MetadataShow full item record
Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when 410% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
Is part ofBritish Journal of Cancer, 2016, vol. 115, núm. 6, p. 716-724
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by-nc-sa (c) van der Putten et al., 2016
Showing items related by title, author, creator and subject.
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer Alonso-Alconada, Lorena; Muinelo-Romay, Laura; Madissoo, Kadri; Díaz-López, Antonio; Krakstad, Camilla; Trovik, Jone; Wik, Elisabeth; Hapangama, Dharani; Coenegrachts, Lieve; Cano, Amparo; Gil-Moreno, Antonio; Chiva, Luís; Cueva, Juan; Vieito, María; Ortega Izquierdo, Maria Eugenia; Mariscal, Javier; Colás, Eva; Castellví, Josep; Cusido, Maite; Dolcet Roca, Xavier; Nijman, Hans W.; Bosse, Tjalling; Green, John A.; Romano, Andrea; Reventós, Jaume; López-López, Rafael; Salvesen, Helga B.; Amant, Frederic; Matias-Guiu, Xavier; Moreno-Bueno, Gema; Abal, Miguel (Biomed Central, 2014)Background: About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we ...
Moiola, Cristian P.; Lopez-Gil, Carlos; Cabrera, Silvia; Garcia, Angel; Van Nyen, Tom; Annibali, Daniela; Fonnes, Tina; Vidal, August; Villanueva, Alberto; Matias-Guiu, Xavier; Krakstad, Camilla; Amant, Frederic; Gil-Moreno, Antonio; Colás, Eva (MDPI, 2018)Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with ...
van der Putten, Louis J. M.; van de Vijver, Koen; Bartosch, Carla; Davidson, Ben; Gatius Calderó, Sònia; Matias-Guiu, Xavier; McCluggage, W. Glenn; Toledo, Gemma; van der Wurff, Anneke A. M.; Pijnenborg, Johanna M. A.; Massuger, Leon F. A. G.; Bulten, Johan (Springer Berlin Heidelberg, 2016)Myometrial invasion (MI) as a percentage (%MI), categorized into <50 or ≥50 %, is an important predictor of prognosis in endometrial carcinoma. Recent studies suggest that tumor-free distance (TFD) to serosa and the absolute ...